Your activity: 26 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Crystalloids and colloids for plasma expansion in adults

Crystalloids and colloids for plasma expansion in adults
Solution
(trade name)
Sodium
(mEq/L)
Potassium
(mEq/L)
Chloride
(mEq/L)
Other
(mEq/L)[1]
pH[1-3] Osmolarity
(mOsm/L)
Mean molecular weight
(Daltons)
Molar substitution* Volume effect
(percent of bolus remaining intravascular)
Plasma volume expansion duration
(hours)
Sodium chloride 0.9% 154 0 154 4.5 to 7.0 308 20 Varies
Lactated Ringer's injection 130 4 109 Calcium 3
Lactate 28
6.0 to 7.5 273 20 Varies
Plasmalyte 140 5 98 Magnesium 3
Acetate 27
Gluconate 23

6.5 to 8.0
(Plasmalyte A)

4.0 to 8.0
(Plasmalyte 148)
294 20 Varies
Normosol-R 140 5 98 Magnesium 3
Acetate 27
Gluconate 23
7.4 295 20 Varies
Albumin (human) 5% 130 to 160[3] ≤2 130 to 160 6.4 to 7.4 309[3] 67,000[4] 70 2 to 4
Gelatin 4% (Gelaspan) 151 103 Calcium 2
Magnesium 2
Acetate 24
7.1 to 7.7 284 30,000 70 to 80 2 to 3
Tetrastarch 6% 130/0.4 (Voluven)Δ 154 0 154 4.0 to 5.5 308 130,000 0.4 100 6[5]
Pentastarch 10% 200/0.5 (Pentaspan Canadian product)Δ 154 0 154 5.0 326 200,000 to 300,000 0.4 to 0.5[6] 145 18 to 24[6]
Hetastarch 6% 600/0.75 (Hespan)Δ 154 0 154 5.9[7] 309 600,000 0.75 100 24 to 36
Hetastarch 6% 670/0.75 (Hextend) 143 3 124 Calcium 5
Magnesium 0.9[8]
Lactate 28
5.9 307[8] 670,000[8] 0.75 100 24 to 36
* Molar substitution is the average hydroxyethyl groups per one glucose unit.
¶ Not available in United States.
Δ In sodium chloride 0.9%.
In Lactated Ringer's injection.
References:
  1. Rhee P. Shock, Electolytes, and Fluid. In: Sabiston Textbook of Surgery, 19th ed, Townsend CM, Beuchamp RD, Evers BM, Mattox KL (Eds), Saunders, Philadelphia 2012.
  2. Heiderich S, Auf der Springe A, Jürgens J, et al. Compatibility of common IV drugs with 6% hydroxyethyl starch 130/0.42 and 4% gelatin. Paediatr Anaesth 2018; 28:87.
  3. Boer C, Bossers SM, Koning NJ. Choice of fluid type: physiological concepts and perioperative indications. Br J Anaesth 2018; 120:384.
  4. Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: Pathophysiologic Basis of Its Role in the Treatment of Cirrhosis and Its Complications. Hepatology 2013; 58:1836.
  5. Voluven [package insert]. Lake Forest, Illinois: Hospira Inc; 2014.
  6. Pentaspan [package insert]. Montreal, Canada: Bristol-Myers Squibb Canada; 2002.
  7. Hespan [package insert]. Irvine, CA: B. Braun Medical Inc; 2013.
  8. Hextend [package insert]. Lake Forest, Illinois: Hospira Inc; 2013.
Graphic 63639 Version 12.0